Introduction

T HE INCIDENCE OF CANINE BRAIN TUMORS IS ABOUT
14.5 per 100,000 patients at risk. 1 The median age at diagnosis of primary tumors is 9 years, 1,2 with a breed predisposition reported in Golden Retrievers and Boxer dogs. 2 The most common primary tumor is meningioma followed by glioma. In dogs, multiple histological subtypes of meningiomas have been described 3, 4 and a grading system has been formulated to attempt a correlation with the outcome.
When looking at the anatomical location, brain tumors can occur in the forebrain (supratentorial) or in the infratentorial space: the latter are defined as intracranial tumors originating in the regions of the brain located in the caudal cranial fossa, inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brainstem, and related structures. 8 Patients affected by infratentorial tumors usually present with ataxia (vestibular or cerebellar), vestibular signs (such as head tilt and nystagmus), cranial nerve deficits (as the nuclei from cranial nerves III to XII are located in the brainstem), and possibly paresis or proprioceptive deficits, if the descending motor tracts or the ascending sensory tracts are affected, respectively. 8 Data regarding the impact of anatomical location on post radiation therapy (RT) outcome is limited, and no studies have specifically looked only at brainstem tumors treated with RT. There is well established evidence that RT causes acute and late side effects and any peritumoural swelling Vet Radiol Ultrasound, Vol. 58, No. 1, 2017, pp 106-116. caused by radiation may be associated with significant adverse effects, particularly in infratentorial locations, 9 likely because of the increased risk of brain herniation in this site. In human medicine, radiation-induced intratumoral necrosis can exacerbate the mass effect until the tumor starts to shrink, especially when this is located adjacent to critical structures or the cerebrospinal fluid (CSF) pathway. 10 There is no data currently available to quantify this risk in veterinary medicine.
Relatively few canine brain tumors are amenable to surgical resection. Nonsurgical management options for brain masses include RT and chemotherapy, including hydroxyurea 11 and lomustine. 12-15 RT has been more extensively investigated. 1, [16] [17] [18] [19] Both definitively fractionated 19, 20 and hypofractionated RT protocols 9, 16 are described. Definitively fractionated protocols are preferred due to concerns about significant late effects, with reported median survival time (MST) ranging from 250 days 20 to 700 days. 19 Available information on palliative medical treatment of canine brain tumor patients suggests that survival times are short 21 (MST of 30-69 days): dogs with infratentorial tumors treated palliatively with glucocorticoids (GC) and phenobarbital achieved a MST of 28 days, which was shorter than the median survival of dogs with supratentorial neoplasms (178 days). However, another study assessing response to radiation in 46 dogs with brain tumors 19 reported that a subset of 12 patients with brain masses located in the caudal fossa achieved a MST of 726 days, which is comparable to other sites in the same study. These data show that the benefit of radiotherapy versus palliative treatment in the management of infratentorial tumors has yet to be defined and they may not have a worse outcome when compared to supratentorial tumors. Furthermore, the tolerability of radiation therapy has not been extensively characterized in such cases. The aim of this study was to retrospectively compare the outcome and survival time in two similar groups of dogs with an imaging diagnosis of infratentorial tumors treated with three-dimensional conformal RT (3D CRT) in addition to GC or systemic GC alone. The authors hypothesized that dogs treated with RT would have had increased survival time (ST) compared to dogs that received systemic GC as the only treatment modality. As a secondary objective of the study, we aimed to determine the frequency of significant acute adverse effects in dogs with infratentorial tumors receiving radiotherapy.
Materials and Methods
Inclusion Criteria
The study followed a retrospective, cohort study design. The clinical databases of three different European institutions (two in the United Kingdom [UK]; one in Switzerland) were searched for dogs presented during 2008-2014, with a presumptive diagnosis of infratentorial tumors on MRI that were treated with RT. For the control group, cases of presumptive infratentorial tumors diagnosed on MRI and treated with GC only were identified on the database of a single institution (UK-based) within the same period of time.
Inclusion/exclusion criteria were determined by a residency-trained medical oncologist (E.T.), a boardcertified medical oncologist (L.B.), a board-certified veterinary neurologist (R.G.) and a board-certified veterinary radiologist (T.W.M.). The sample size was determined by the available population that met the inclusion criteria, due to the retrospective nature of the study. The project was approved by the University of Liverpool Veterinary Research Ethics Committee. Dogs could only be included in the study if they met the following inclusion criteria: availability of magnetic resonance images for review; identification on MRI of a mass located in either the brainstem and/or cerebellum and limited to the caudal fossa, identified as a tumor based on MRI findings; completeness of medical records (including details of staging procedures, additional treatment, follow-up examinations).
Dogs were assigned to the radiotherapy group when RT was used as the treatment modality of choice and there was a minimum follow-up time of 6 months (or until death if shorter). Patients receiving chemotherapy with hydroxyurea were not excluded from the RT group due to the lack of evidence of efficacy of this drug in the gross disease setting. Patients receiving surgery were also not excluded, because of known residual disease and to assess the tolerability of RT in this setting, but were excluded from survival analysis. Dogs were not excluded on the basis of having received additional supportive treatment during or after delivery of RT with GC, diuretics, analgesics, gastroprotectants, or any additional medication such as topical treatment for otitis externa (as these drugs are commonly used in the supportive treatment of brain tumors and managing RT side effects) and were similarly not exclusion criteria for the control group. Dogs could also receive GC prior to MRI diagnosis.
Dogs were assigned to the control (glucocorticoid) group if they were discharged from the hospital after being diagnosed with an infratentorial tumor on MRI and had been palliatively treated with GC with or without diuretics, analgesics, or gastroprotectants for a minimum of 48 h. Dogs could also receive GC prior to MRI diagnosis. The minimum follow-up time was 6 months (or until death if shorter). Survival time was calculated for both groups from the time of treatment initiation (either RT or GC) until death for any causes.
For all included dogs, medical records were reviewed and data harvested included neurological signs on presentation (specifically, presence or absence of head tilt and other cranial nerve deficits; presence of proprioceptive deficits and cerebellar signs, namely hypermetria and nystagmus), MRI findings (as specified below), treatment received and RT protocol, and total dose (for the RT group only). Where available, hematology, biochemistry and additional imaging findings were also reviewed. For the purpose of comparison between groups, the clinical severity of neurologic dysfunction at the time of presentation was graded 1 by a board-certified neurologist (R.G.) following retrospective review of the medical records on a scale of one to three: one (mild) = mild neurologic deficits such as head tilt or proprioceptive deficits only, with the animal alert and ambulatory; two (moderate) = overt clinical neurologic dysfunction present in an ambulatory animal without depressed level of consciousness (i.e., paresis, vestibular or cerebellar ataxia, hypermetria, cranial nerve deficits, nystagmus); and three (severe) = debilitating neurological deficits such as ataxia with leaning or falling, nonambulatory paresis, dysphagia, or depressed mentation. Follow-up information was gathered from medical records at the time patients were reexamined at the treating center and by phone calls to owners (if patients were known to be still alive) or referring veterinarians.
All MRI images (pre-and postcontrast) were reviewed by a board-certified veterinary neurologist (R.G.) and a board-certified veterinary radiologist (T.W.M.). Magnetic resonance imaging features were classified on the consensus opinion of both reviewers, who were blinded with regards to the final diagnosis (presumptive or confirmed on histopathology) and the outcome after treatment. The images were initially reviewed independently and then agreement reached by consensus; the image order was randomized. Measurements were performed once at the consensus review. The masses were classified according to their anatomical site as basilar, in the cerebellopontine angle, in the lateral apertures, in the cerebellum, over the cerebellar convexity, or through the foramen magnum, as previously described. 4 All masses were further characterized as intra-or extraaxial and in view of the image characteristics, a presumptive diagnosis of meningioma, glioma or choroid plexus tumor was made. The MRI criteria for accurately predicting the presence of a primary brain tumor and the type were used as reported in the literature. [22] [23] [24] The presence of either transtentorial or foramen magnum herniation was recorded as well as the presence of obstructive hydrocephalus and syringohydromyelia. The severity of the perilesional oedema was graded as absent, subtle, mild, moderate or severe on the basis of the consensus between two of the authors (R.G. and T.W.M.). The MRI features were subsequently correlated with outcome.
Treatment and Follow-Up
Planning and treatment protocols were standardized for included dogs. Radiation treatment was delivered using the linear accelerator present in each center (Clinac 600C, or 2100, Varian Medical Systems, Palo Alto, CA). All treatments were carried out at 6 MV, and were 3D planned from Computed tomography ([CT] fused with [or compared with] MRI images) using Pinnacle version 8/9 (Pinnacle, Philips Radiation Oncology Systems, Philips Healthcare, NA); Cad-Plan (Varian) version 2.5 and Eclipse External Beam Planning system version 8.1 (Varian Oncology Systems, Palo Alto, CA), with the intent to include at least 95% of the planning treatment volume (planning treatment volume based on clinical target volume plus 0.3-0.5cm) in the 95-105% isodose, ideally in the 98-102% isodose. Planned dose heterogeneity was less than 10%. Planning technique was similar for the three participating institutions, using standardised software packages: plans utilized two to four coplanar beams, with beam collimation using multileaf collimator (MLC) or manual blocks and beam modification using dynamic wedges when appropriate. For planning CT and treatment delivery, patients were placed under general anaesthesia, positioned in sternal recumbency and immobilized. Immobilization was achieved using the following: a thermoplastic mask and a customized head support, secured to a plastic head-frame with four points of fixation, 25 a head rest only and a vacuum cushion or a bite block together with a vacuum cushion. 26 Portal imaging was carried out at least twice during the treatment protocol to verify position, but no adjustments were made to any patient positioning during treatment course.
The gross tumor volume (GTV) was delineated by the oncologist responsible for treatment planning using coregistered or in parallel viewed contrast enhanced CT images and/or MRI, and clinical target volume (CTV), accounting for subclinical microscopic disease extension, was defined. Gross tumor volume and CTV volumes were generated by planning software. Slice thickness and post-imaging algorithms also varied between the institutions but followed the standard protocols of the participating institutes. Pre-and post-contrast images were routinely acquired for all cases. Gross tumor volume and CTV were defined using CT and MRI. Gross tumor volume was contoured based on T1 (or T1 with contrast) images. A margin of 1-2 mm of normal tissue, including questionable tissue, was added to the GTV to create the CTV. The CTV-margin was extended threedimensionally by 3-5 mm to define the planning target volume (PTV). Organs at risk were contoured (tympanic bullae, brain, spinal cord, optic chiasma). Prescriptions varied slightly dependent on individual institutional policy and clinician preference (based on relative tumor size and normal brain exposure). Tumor volumes were calculated by the planning software from the contoured GTV. Direct measurement of tumor volumes from MRI was not carried out.
Radiation-related toxicity was graded according to the Veterinary Radiation Therapy Oncology Group (VRTOG) scheme treatment 27 during the course of RT, 2 weeks post-completion, and monthly for the first 3 months after treatment. Additional follow-up visits were scheduled 3 to 6 months thereafter for the first year depending on owners' compliance and finances. Clinical response to RT was defined based on improvement or resolution of clinical signs and classified as complete response (CR) if resolution of the neurological signs showed at presentation occurred, partial response (PR) if there was a clinical improvement but not complete resolution of signs, stable disease (SD) if no changes were documented and progressive disease (PD) if progression of clinical signs was observed. If follow-up imaging was used, a response was defined based on the most recent version of the RECIST criteria 28 (CR, complete resolution of all the target lesions; PR, reduction of at least 30% of measurable lesions; SD, <30% reduction of measurable lesions and PD when a 20% increase of the lesions was documented).
Statistical Analysis
Statistical analysis was performed by one of the authors (T.W.M.) using commercial statistical software (IBM SPSS Statistics for Windows, Version 21.0. IBM Corp, Armonk, NY). Descriptive statistics were calculated for variables as appropriate; continuous data were summarized as mean and standard deviation if normally distributed or median and interquartile range (IQR) if non-normally distributed. Categorical data were collected into appropriate groups and expressed as frequencies with 95% confidence intervals (95% CI). Normality of distribution for continuous variables was assessed through graphical analysis and assessment of a Kolmogorov-Smirnov test. In both groups, ST was calculated from the time treatment (either RT or palliative) was started until death. Dogs that were alive at the time of data collection were considered as censored, with MSTs calculated from Kaplan-Meier product limit (survival) analysis. 29 Patients were censored at the last date of contact.
Comparison of survival times and association of survival with independent variables were assessed with the Log Rank test for categorical variables and Cox regression analysis for continuous variables. 30 Independent variables included MRI features (herniation of the cerebellum, obstructive hydrocephalus, syringohydromyelia, perilesional oedema) and presence or absence of neurological signs (head tilt, other cranial nerve deficits, neurological grade, presence of proprioceptive deficits and cerebellar signs, specifically hypermetria and nystagmus). All independent MRI and neurological variables were assessed within each group. The presence of ataxia was considered to be too nonspecific to be statistically evaluated as an independent variable within the neurological signs.
Analyses for RT dose (48 Gy or less) and tumor volume (GTV) was restricted to those dogs that received radiation and GC only (because tumor volumes were calculated by the planning software from the contoured GTV and this process was not undertaken for untreated patients). Direct measurement of tumor volumes from MRI was not carried out.
P < 0.05 was considered significant for all analyses.
Results
Signalment and Clinical Signs
Nineteen cases were initially included in the RT group: three cases were excluded as no MRI was available for review and one additional case was excluded after review of the MRI was inconsistent with an infratentorial location. Of the 15 remaining, six, seven and two cases belonged to three different institutions, respectively. For the control group, 20 cases were initially included but five dogs were excluded as euthanasia was performed at the time of diagnosis at the owner's request. Thus there were 15 dogs in each group for subsequent analyses.
The CT scanners varied among hospitals (Siemens Somaton Volume Zoom 4-slice, Malvern, PA, Siemens Somaton Spirit 2-slice, Malvern, PA and GE Bright Speed 8-slice, Boston, MA). The same high field MRI scanner was used for the control group and some of the cases receiving RT and GC (Siemens Magnetom Harmony 1T high field, Malvern, PA). The majority of the MRI images for the group receiving RT and GC were provided by the original referring practices (hence the technical information could not be retrieved for the individual cases) and studies were not repeated unless considered inadequate.
In the RT group (15 dogs), median age at diagnosis was 7 years (range 2-15 years) and median body weight 21 kg (range 5.7-38.3 kg). The median duration of follow up was 677 days (range 46-1825 days). There were 11 females (10 neutered females, one intact female) and four males (two intact males, two neutered males). The most common breeds were Boxer (three), English Springer Spaniel (two), Border Collie (two) and one each of the following: Labrador Retriever, Belgian Shepherd, German Shepherd, Miniature Poodle, English Setter, with the remaining three being mixed breed dogs. Neurological signs at the time of diagnosis included head tilt (11), proprioceptive deficits (five), cranial nerve deficits (nine), ataxia (five), nystagmus (one), hypermetria (one), and dysphagia (one). No changes in mentation were reported. The severity of the neurological dysfunction at the time of diagnosis was mild in four cases, moderate in 10 cases and severe in one case. Additional investigations were performed in 12/15 cases (80%) in the RT group: additional imaging was performed in five cases, including: thoracic radiographs (two), abdominal radiographs (one), abdominal ultrasound (two), thoracic CT (one) and whole body CT (one). No evidence of other primary or metastatic disease was found in these cases. Hematology and biochemistry were performed in 11 cases (73%), showing the followings: mild neutrophilia (three), mild lymphopenia (two) and mild thrombocytopenia (one); the biochemistry findings were limited to a mild to moderate increase in alkaline phosphatase ([ALP] six), a mild increase in alanine aminotransferase ([ALT] three), mild elevation in blood urea nitrogen (one) and creatinine (one) and mild hypercholesterolemia (two). Cerebrospinal fluid tap was performed in two dogs, without showing any abnormal findings. All the dogs in the RT group also received oral prednisolone (Prednicare R , Animalcare Group, UK).
Dogs in the control group did not receive RT due to their owners declining treatment for financial/personal reasons. In this group (15 dogs), median age at diagnosis was eight years (range 4-10 years) and median body weight was 29.8 kg (8.6-61.1 kg). The median duration of follow-up was 89 days (range 5-940 days). There were seven neutered females and eight males (three intact, five neutered). The most common breed was the Boxer (five) and there was one each of the following breeds: Lhasa Apso, West Highland White Terrier, German Shepherd, Border Collie, Border Terrier, Golden Retriever, Rhodesian Ridgeback, Dogue de Bordeaux, with the remainder being cross-breed dogs (two). Neurological signs at presentation included head tilt (seven), proprioceptive deficits (seven), cranial nerve deficits (eight), ataxia (seven), nystagmus (four), hypermetria (two) and dysphagia (one). No changes in mentation were reported. The severity of the neurological dysfunction at the time of diagnosis was mild in three cases, moderate in 11 cases and severe in one case. Additional investigations in the GC only group (including hematology, biochemistry, and additional imaging) were performed in 7/15 cases (46%). Hematology was performed in six cases (40%) and biochemistry in seven cases (46%). Hematology only showed mild thrombocytosis (one) and mild neutrophilia (one). Biochemistry showed a mild hypercholesterolemia (three) and a mild increase in blood urea nitrogen (two), total calcium (two), ALT (two) and ALP (one). Three dogs also showed a mild hypoproteinaemia with normal albumin levels. Coagulation profile and a thyroid function test were performed in one and two dogs respectively and found to be within normal limits. Thoracic radiographs were performed in one dog for staging purposes and found to be negative for distant metastatic disease. No CSF sampling was performed in any case. All the dogs in the control group received oral prednisolone (Prednicare R , Animalcare Group, UK) alone or in association with analgesics, diuretics, and gastroprotectants. None of the dogs in either group received anticonvulsants before or after the diagnosis of a brain tumor. Other treatments included chemotherapy, analgesics, gastroprotectants and topical medication.
MRI Review
Both reviewers were agreed on the final presumptive diagnosis in all cases. In the RT group, 10 masses were located in the brainstem; six were at the cerebellopontine angle, two in the lateral apertures, one basilar and one through the foramen magnum. Four masses were located over the cerebellar convexity (all extradural) and one was located in the cerebellum (intradural). Magnetic resonance imaging features of the masses were suggestive of a presumptive diagnosis of meningioma (Fig. 1 ) in 12 dogs (histologically confirmed in two patients), choroid plexus tumor in two dogs and glioma (suspected astrocytoma) in one dog. In three cases, mild herniation of the cerebellum through the foramen magnum was noted and in five dogs, mild obstructive hydrocephalus was identified. Syringohydromyelia in the cervical spinal cord were also identified in 10 cases. Perilesional oedema was graded as subtle in eight cases, mild in three and moderate in four cases.
In the control population, 10 masses were located in the brainstem and all were extradural; five were at the cerebellopontine angle, two basilar and three through the foramen magnum. Three masses were located over the cerebellar convexity (all extradural) and two were located in the cerebellum (intradural). The MRI features of the masses were suggestive of a presumptive diagnosis of meningioma in 13 dogs (Fig. 1) and glioma (suspected astrocytoma) in two dogs. In four cases, mild herniation of the cerebellum through the foramen magnum was detected and in seven dogs, mild obstructive hydrocephalus was noted. Syringohydromyelia in the cervical spinal cord were also identified in 11 cases. Perilesional oedema was graded as subtle in five cases, mild in four and moderate in six cases.
Treatment
Radiation therapy. Treatments were prescribed and planned by three of the authors, two board-certified radiation oncologists (Je.B and Ju.B) and one board-certified medical oncologist (L.B.).
Pinnacle version 8 (for those cases treated until 2013), then 9 for the most recent cases (Pinnacle, Philips Radiation Oncology Systems, Philips Healthcare, NA) was used in six cases; Cad-Plan (Varian) version 2.5 in seven cases and Eclipse External Beam Planning system version 8.1 (Varian Oncology Systems, Palo Alto, CA) in the remaining two cases. Plans utilized two to four beams, with beam collimation using MLC in nine (60%) cases or manual blocks in the remainder of cases (six, 40%) and beam modification using dynamic wedges when appropriate. Immobilization was achieved using a thermoplastic mask and a customized head support in six cases. A head rest only and a vacuum cushion was used in seven cases and a bite block together with a vacuum cushion in two cases. The RT protocols used were as follows: 12 fractions of 4 Gy each on Monday, Wednesday, Friday to a total dose of 48 Gy (six dogs); 16 daily fractions of 3 Gy each to a total dose of 48 Gy (two dogs); 15 daily fractions of 3 Gy each to a total dose of 45 Gy (three dogs); 16 daily fractions of 2.8 Gy each to a total dose of 45 Gy (one dog); one daily fraction of 5 Gy and 8 daily fractions of 4 Gy to a total dose of 37 Gy (one dog); 20 daily fractions of 2.25 Gy (one dog) to a total dose of 45 Gy; two daily fractions of 3 Gy each and 18 daily fractions of 2 Gy each to a total dose of 42 Gy (one dog). Daily fractions were delivered Monday to Friday, with no treatments at weekends.
Median tumor volume could be assessed in 14/15 cases and was 3.1 cm 3 (range, 1.85-4.41 cm 3 ). In one case, RT treatment was planned based on the original MRI to treat residual disease following debulking surgery, hence tumor volume at the start of RT treatment could not be determined. The median dose to the GTV was 47.9 Gy (range, 45.0-48.0 Gy) and the median dose to the PTV was 47.5 Gy (range, 45.0-47.9 Gy).
All dogs received prednisolone (Prednicare R , Animalcare Group, UK) at a dose between 0.5-1.5 mg/kg orally q12-24 hours, to manage potential tumor oedema during RT. In 12 cases, treatment was started before RT, whereas in three cases GC were started concurrently. Glucocorticoids were continued for at least 6-8 weeks after completion of RT treatment. Except in one case, a variable improvement (ranging from mild to significant) of the neurological signs was observed during the RT course. In this group, two dogs received gastroprotectants (one received famotidine and one omeprazole).
Acute side effects during or in the two weeks following therapy were recorded in 3/15 dogs (20%) and were limited to mild, bilateral otitis externa and cutaneous erythema of both ear pinnae, classified as grade II according to the VR-TOG toxicity scheme 27 (moderate external otitis requiring topical medication). These dogs all received a total radiation dose of 48 Gy (two in Monday-Wednesday-Friday fractions of 4 Gy each and one in 16 daily fractions of 3 Gy each). However, four more dogs experienced recurrence or worsening of clinical signs within 6 months following completion of radiation, which may reflect more delayed acute RT effects, increasing the total number to 7/15 dogs (47%). Oral tramadol (2 mg/kg BID) to treat presumptive pain and discomfort after RT treatment was used in six dogs (40%).
Additional Treatment
Additional treatments in the RT group included surgery with a combined suboccipital and right-sided rostrotentorial craniectomy in one dog and a suboccipital craniectomy alone in another dog. For those two dogs receiving surgery, histopathology was compatible with anaplastic (grade III) and microcystic (grade I) meningioma, according to the WHO classification. 3 MRI review was suggestive of a meningioma in both cases. RT was started 30 and 15 days after surgery, respectively. These dogs were excluded from survival analysis, given they received RT as an adjuvant to surgery; both patients were alive at the time of analysis (follow-up, 332 and 1254 days).
Two dogs received chemotherapy with oral hydroxyurea (Hydrea R , Bristol-Myers Squibb, Canada), used at a dose of 20 and 30 mg/kg SID, respectively. In both cases, a complete blood cell count was performed monthly to check for potential myelosuppression or other hematological toxicity, with no major changes recorded. In one case, chemotherapy was started at the time of diagnosis, followed by RT nine days later, and lasted for 64 days. Treatment was discontinued 35 days after completion of the RT treatment. The other dog received hydroxyurea from 581 days after completion of RT treatment, for 83 days, due to recurrence of neurological signs.
Response to Treatment and Progression of Clinical Signs
The majority of dogs (12/15) started GC treatment before RT, including the two patients that underwent surgery. The median time between steroid treatment and start of RT was 10 days (range, 5-42 days). In no case was a marked improvement in clinical signs documented prior to RT. Not all dogs were routinely reimaged after completion of radiation. Therefore, the majority of responses were clinically evaluated on the basis of improvement in clinical and neurological signs and were subjective. Three patients (20%) showed apparent clinical CR; 10 (66%) showed PR and one patient SD. In one case, deterioration of clinical signs was documented 38 days after treatment course was completed and was compatible with either PD or RT acute side effects. Within the group, three cases had imaging followup: the initial clinical response was compatible with PR in one and CR in two dogs. They underwent contrastenhanced CT following RT and response defined according to the RECIST 1.1 criteria. 28 Of these cases, the one showing a clinical PR had repeat CT scans performed 60 and 581 days after completion of RT treatment due to recurrence of neurological signs. Computed tomography findings at 60 days were suggestive of brain oedema, with no overt changes in the mass size and density, suggesting SD. After 581 days, imaging findings were suggestive of either PD or brain necrosis. Specifically, they showed the presence of a contrast enhancing mass in the caudal aspect of the cerebellum, extending into the caudal fossa, with a large, hypoattenuating and larger cystic component affecting the entire cerebellum along its axis. The cyst was marginally larger than before. This dog had received a total of 48 Gy over 16 daily treatments. No histopathological diagnosis was obtained and no post-mortem was performed. At this point, the dog received hydroxyurea and prednisolone (0.5 mg/kg SID): treatment was discontinued 83 days later due to clinical deterioration. The two patients showing clinical CR had a repeat CT scan 141 and 142 days after completion of RT to document response and, in both cases, imaging findings were compatible with SD.
Four patients were restarted on prednisolone (dose range 0.5-1.5 mg/kg SID): in one case, the patient received GC 300 days after completion of radiation, when PD was suspected based on clinical examination. The other three patients restarted GC 30 and 150 days after RT was discontinued. Glucocorticoid administration resulted in a marked improvement of clinical signs and these patients were maintained on the lowest possible prednisolone dose (usually every other day dose) until death. One patient received a hypofractionated course of radiation (one daily fraction of 5 Gy and 8 daily fractions of 4 Gy to a total dose of 37 Gy). This dog survived for 365 days and was then euthanased due to recurrence of neurological signs.
Control Group
For the control group, prednisolone dose ranged from 0.2-0.5 mg/kg every other day or q24-12 h to 1-1.2 mg/kg q24-12 h. This resulted in a transient, mild to moderate improvement in clinical signs in most of the cases. Additional treatment in three cases (20%) consisted in analgesics (two cases), diuretics and gastroprotectants (ranitidine or omeprazole, two cases). Tumor volumes were not available for the control group, as volumes were calculated by the planning software from the contoured GTV in those patients receiving RT. As this process was not undertaken for those patients receiving prednisolone only, these data were not available for review. Direct measurement of tumor volumes from MRI was not carried out. However, features of the brain tumors on MRI were subjectively similar to those of dogs belonging to the RT group.
Survival Time and Prognostic Indicators
Thirteen dogs in the RT group and 15 in the control group were included in the survival data analysis. As calculated with Kaplan-Meier product limit survival, the overall MST was 294 days (95% CI 42-545). The MST in the RT Group was 756 days (95% CI 209-1302) vs. 89 days (95% CI 35-143 days) for the group that received palliative treatment with prednisolone alone (Fig. 2) . The difference in survival was statistically significant (Log Rank test P = 0.001). When comparing the total dose of radiation (48 Gy vs. lower), MST for the 48 Gy group was 1080 days, and for the less than 48 Gy group, 258 days. However, statistically, dose did not affect survival (Log Rank test P = 0.14, Table 2 ). In addition, tumor volume did not affect survival in the RT group.
The neurological score assigned to each patient was not significantly associated with survival (Log Rank test P = 0.17). None of the other independent variables considered as prognostic factors showed a significant association with survival times (Table 1 ). The small number of cases precluded a multivariable analysis for the RT group. Seven dogs in the RT group were euthanased because of progression of clinical signs, and two patients were euthanased because of acute onset of gastrointestinal signs possibly secondary to pancreatitis and a mammary tumor, respectively. Six dogs in the RT group were still alive at the time of analysis, of which two receiving surgery were excluded from survival calculations: median follow-up was 533.5 days (range 332-1825 days). Thirteen of the dogs in the control group were euthanased because of progression of the neurological signs, with two survivors at the time of analysis (follow-up, 186 and 194 days, respectively). The characteristics of the two groups are summarized in Table 2 .
Discussion and Conclusions
This study suggests that the use of RT for brainstem tumors provides a survival advantage over prednisolone alone, and is not associated with an unacceptably high frequency of significant acute radiation side effects. However, neither the severity of neurological signs at diagnosis, nor any of the investigated clinical, imaging, or treatment variables (Table 1) were significantly associated with ST: the study may simply have lacked the power to identify associations. The MST in the current study (756 days) is similar to the reported MST of 726 days 19 for 12 (presumptively diagnosed) meningiomas in the caudal fossa treated with similarly fractionated radiotherapy. It is longer than the reported MST of 250 days for tumors in any location. 20 This further reinforces that RT is a suitable treatment for canine infratentorial brain tumors. In addition, the patients belonging to our control group also achieved a longer survival compared to dogs treated palliatively in a previous study including tumors in any site. 21 This may reflect the different study populations or the small numbers of patients involved.
Limitations of this study include the lack of a histopathological diagnosis in the majority of cases, the retrospective nature, the heterogeneity in the RT protocols used, the small number of patients, the lack of direct comparison of tumor volumes between groups, the lack of repeat MRI in most cases to assess response to treatment and late side effects and the lack of post-mortem examination. Additionally, some of the information ideally required for complete radiation reporting as detailed by Keyerleber et al. 31 was not retrievable from the medical records.
Most brain tumor studies in veterinary medicine do not have histological diagnoses. 9, 17, 19, 20 Biopsy is rarely performed due to the lack of availability of stereotactic brain biopsy techniques. Infratentorial masses are less readily accessible for biopsy than supratentorial and performing this procedure can result in higher complication rates. 32 The reported accuracy of MRI for correctly predicting the presence of a primary brain tumor is 100%, 2 with a 70-96% accuracy for predicting the correct tumor type. 22, 23 As a result, MRI features of intracranial lesions are often used as the basis for presumptive diagnosis. 33 However, it is reported that cerebral vascular accidents can be misdiagnosed as gliomas on MRI 34 and no standard MRI features are highly specific for vascular lesions. 35 In the current study, diagnosis was presumptive in most cases. Therefore, in order to ensure robust imaging diagnoses, the imaging studies were reviewed by two board-certified specialists (one imager and one neurologist, blinded to the original diagnosis), and both diagnosed an intracranial mass in all cases. Most tumors were presumptively diagnosed as meningiomas due to the extradural location. A histopathological diagnosis was available in only two cases (one low grade and one anaplastic meningioma) and confirmed the presumptive diagnoses of meningioma made on MRI (both on original reporting and on review for the study).
In the current study, the RT protocol was dependent on the institution but the planning technique was similar for the three participating institutions, using standardized software packages, with the majority of plans being relatively simple coplanar beam plans using MLCs to shield organs at risk. The total RT dose was 48 Gy (in 3 or 4 Gy fraction) in more than half of the cases, with the remaining dogs receiving a total dose of less than 48 Gy. Independent of the fractionation scheme, the nine patients receiving 48 Gy survived longer than those receiving a lower total radiation dose but this difference was not statistically significant. The intrinsic heterogeneity of our group (prescription dose and fractionation, tumor volume and type) is a clear source of bias and the data should be interpreted with caution. It is also worth considering the biological effective doses (BED) of our protocols, in comparison to standards in human medicine. The recent QUANTEC (quantitative analysis of normal tissue effects in the clinic) review produced recommendations for the RT treatment of various normal tissues, including the brainstem, based on the clinical observations of human patients developing delayed complications after therapy (suspected tissue necrosis with symptoms). It appears 36 that the human brainstem can tolerate 3D conformal external beam radiation doses of 54 Gy (1.8-2 Gy fraction), with a tolerance of doses up to 59 Gy for smaller volumes. The risk of local complications is significantly increased for doses over 64 Gy. Thus the α/β ratio for the brainstem is estimated to be between 2 Gy and 2.5 Gy. The BED for a 54 Gy (2 Gy fraction) course is 64.8 Gy for early responding tissues (tumor tissue) and 108 Gy (α/β = 2) for late responding tissue (the brainstem itself). In comparison, our 48 Gy protocols have a comparable BED for early responding tissue of 67.2 (4 Gy fraction) and 62.4 (3 Gy fraction), but a higher BED for late responding tissues of 144 (4 Gy fraction) and 120 (3 Gy fraction), suggesting a probable higher complication risk in long-term survivors. Unfortunately, the late complication rate could not be evaluated in this study, as most patients did not have repeat imaging or necropsy, but the long MST suggests that such effects do not eliminate clinical benefit. No standards exist in veterinary radiation oncology for CNS irradiation and historical studies have mostly reported 12-16 fraction RT schedules. One patient received a hypofractionated course of radiotherapy, based on a published protocol. 9 In fact this dog received 9 fractions (which is less than definitive protocols but represents a smaller fraction size compared to standard hypofractionated protocols). The protocol was chosen so that the total dose and associated estimated BED would still be high for early responding tissues but moderate for late responding tissues. This patient might have created some heterogeneity in our population and subsequently affected the individual and overall outcome.
The absence of comparison of tumor volumes between the two groups represents another limitation of the study:
we cannot rule out that dogs with larger tumors were more likely not to receive RT. However, tumor volume did not impact survival in the RT-treated group.
None of the MRI factors influenced ST in either the RT or the GC alone group, but the findings may have introduced bias if clinicians were less likely to encourage clients to pursue RT. Although more dogs in the control group had obstructive hydrocephalus with subsequent raised ICP on MRI, the neurological score and severity of signs was not statistically different between groups. Response to treatment was defined by clinical response, as repeat imaging was available for only three patients. However, most of the patients experienced clinical PR or SD and the two experiencing a clinical CR did not show CR on imaging, suggesting overestimation of the clinical response. Only four patients received RT in combination with surgery or chemotherapy: further studies are necessary to confirm whether combined therapies can provide a survival advantage.
No dogs had significant acute complications during treatment: this is often a clinical concern, as local inflammation or oedema could theoretically result in life-threatening complications during treatment of brainstem tumors. All the patients in the RT group also received GC and this could have had an impact on outcome and prognosis: using this drug may have prevented or reduced complications due to radiation and have contributed to underestimation of acute side effects. Additional treatment with omeprazole in one dog in the RT group may have influenced the outcome, as this drug is known to decrease CSF production. 37 Some dogs also received oral analgesics: if this presumed discomfort was included as a reflection of side effects (rather than due to the presence of the tumor itself), the overall incidence would be 87%.
Recurrence/deterioration in neurological signs occurred within 6 months of radiotherapy in three cases, due to either PD or acute radiation effects. In both this cohort and long-term survivors, lack of repeat MRI or postmortem may also have contributed to underestimation of radiation toxicity. In addition, the retrospective nature of the study may mean side effects not requiring medical intervention were underreported and therefore underestimated.
In conclusion, this study suggests that RT provides a survival advantage over palliative treatment with GC in dogs with infratentorial neoplasia. When treated with definitive RT protocols, brain tumors in the infratentorial space may have as good a prognosis as in any other tumor location and the perceived risks of treating brainstem tumors with RT have possibly been overestimated. Treatment was generally well tolerated, and most patients experienced an improvement in neurological signs. This study was unable to find a significant association between radiation dose and survival. The most appropriate definitive radiation protocol for canine brain tumors is unknown, but smaller fractions are less likely to be associated with significant late side effects when normal tissues are exposed to radiation. Further studies are needed to confirm the efficacy of RT in the treatment of infratentorial tumors and to evaluate multimodality therapy. 
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